Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 9/20 | 0.47 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1953208 | 0.89 | MAPK1 (0.48) | MAPK1GPR88LMNAHTTOPRK1 | |
| SCHEMBL4338097 | 0.85 | MAPK1 (0.45) | MAPK1GPR88LMNAHTTOPRK1 | |
| SCHEMBL4341623 | 0.85 | GPR88 (0.47) | MAPK1GPR88LMNAHTTOPRK1 | |
| SCHEMBL16830004 | 0.85 | LMNA (0.51) | MAPK1GPR88LMNAHTTOPRK1 | |
| SCHEMBL16830003 | 0.85 | LMNA (0.51) | MAPK1GPR88LMNAHTTOPRK1 | |
| SCHEMBL8540915 | 0.82 | LMNA (0.49) | MAPK1GPR88LMNAHTTOPRK1 | |
| SCHEMBL8540917 | 0.82 | LMNA (0.49) | MAPK1GPR88LMNAHTTOPRK1 | |
| SCHEMBL1720120 | 0.82 | MAPK1 (0.43) | MAPK1GPR88LMNAHTTOPRK1 | |
| SCHEMBL4536126 | 0.82 | MAPK1 (0.43) | MAPK1GPR88LMNAHTTOPRK1 | |
| SCHEMBL1720123 | 0.82 | MAPK1 (0.43) | MAPK1GPR88LMNAHTTOPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612236-B2 | Method for producing optically active bisamidoalcohol compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-11-03 | — | — | US | disclosed |
| US-20070100163-A1 | Reacting an optically active aminoalcohol compound with a diester compound in the presence of a lithium compound wherein the lithium compound is selected from lithium hydroxide, a lithium alkoxide and a lithium halide; product can be efficiently and inexpensively produced | SUMITOMO CHEMICAL COMPANY, LIMITED | 2007-05-03 | — | — | US | disclosed |
| EP-1698616-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE BISAMIDO ALCOHOL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070100163-A1 | Reacting an optically active aminoalcohol compound with a diester compound in the presence of a lithium compound wherein the lithium compound is selected from lithium hydroxide, a lithium alkoxide and a lithium halide; product can be efficiently and inexpensively produced | CCNL2, ARL1, ACSL3 | MAPK1 1770/4885GPR88 3058/4885LMNA 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.